Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-22
2005-02-22
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06858618
ABSTRACT:
The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 6316460 (2001-11-01), Creekmore et al.
patent: 6696084 (2004-02-01), Pace et al.
patent: 0 521 471 (1993-01-01), None
Koizumi et al., “Clinical Efficacy of Fluvastatin in the Long-Term Treatment of Familial Hypercholesterolemia”, American Journal of Cardiology, vol. 76, No. 2, 1995, pp. 47A-50A.
Kitatani et al., “A 4-Year trial of simvastatin in the treatment of patients with heterozigous of Familial Hypercholesterolaemia”, Current Therapeutic Research, vol. 57, No. 1, 1996, pp. 62-71.
Koizumi et al., “Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia”, Atherosclerosis, vol. 100, No. 1, 1993, pp. 65-74.
Stein et al., “Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial”, Journal of American Medical Association, vol. 281, No. 2, Jan. 13, 1999, pp. 137-144.
Watanabe et al., “Synthesis and Biological Antivity of Methanesulfonamide Pyrimidine-And-N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-Heptenoates, A Novel Series of HMG-COA Reductase Inhibitors”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd., vol. 5, No. 2, 1997, pp. 437-444.
Olsson et al., “ZD4522: A new HMG-CoA reductase inhibitor-causes rapid and profound reductions in plasma LDL-C levels in patients with primary hypercholesterolaemia”, European Heart Journal, vol. 21, no. Abstract Supplement, Aug., 2000, p. 156.
Pears et al., “Dose-ranging study of the HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercolesterolemia”, Canadian Journal of Cardiology, vol. 16, No. Supplement F, Sep. 2000, p. 196F.
Stein et al., “ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia”, Journa of the American College of Cardiology, vol. 37, No. 2, Supplement A, Feb. 2001, p. 291A.
Stein et al., “ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia”, Journal of American College of Cardiology, vol. 37, No. 2, Supplement A, Feb. 2001, p. 292A.
Ollson et al., “A new statin: A new Standard”, Clinical Cardiology, vol. 24, No. 8, Supplement 3, Aug. 2001, pp. III-18-III-23.
Hutchinson Howard Gerard
Raza Ali
AstraZeneca AB
Henley III Raymond J.
Morgan & Lewis & Bockius, LLP
LandOfFree
Use of rosuvastatin (zd-4522) in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rosuvastatin (zd-4522) in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rosuvastatin (zd-4522) in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3455831